An interventional study of Photobiomodulation with blue light in Donor Site Complication, Burn and Photobiomodulation Therapy, sponsored by AUSL Romagna Rimini. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-06.
Sponsored by AUSL Romagna Rimini · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Burns with a site in Italy — 3 open to participants now, 6 under way, 1 of them phase 3. Burns · Italy.
Among the 18 studies in Burns with a site in Italy, this one is the 8th largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2025, is one of 5 with no phase, and was the 18th registered.
906 studies on the registry are indexed under Burns; 165 are open to participants now.
Browse Burns studies →3 of the 18 studies in Burns with a site in Italy are open now. Recruiting first, the newest first:
CUTISS AG · Sites in Italy, Belgium, France and 6 more countries
Ages 12+
CytoSorbents, Inc · Sites in Italy, Austria, Germany and 3 more countries
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 87 Burns studies recruiting now, 38 (44%) set no upper age limit and 38 (44%) stop at 75 or younger; 17 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2025.
This study's planned enrollment of 25 is below the median of 40 across 664 interventional studies indexed under Burns.
Median enrollment 48 across the 14 interventional studies, 44 across the 4 observational. Of the 9 that completed or were terminated, 2 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 18 have an industry lead sponsor. The 10 most frequent:
AUSL Romagna Rimini is the lead sponsor of 13 studies on the registry; 5 are open to participants now.
AUSL Romagna Rimini has 1 study filed under Burns — fewer than ten, so there is no comparison to draw.
1 of the studies in Burns with a site in Italy that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06745557Phase 3CUTISS AGPhase III Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Adults and Adolescents | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies in Burns with a site in Italy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn whether blue light (BL) photobiomodulation can improve the healing of donor site (DS) wounds in patients with burn injuries who are treated surgically. This study will investigate whether adding BL therapy to the usual treatment can improve healing and patient outcomes in adult patients with intermediate and deep burns.
The main questions it aims to answer are:
Researchers will compare DS areas treated with standard care alone to DS areas treated with standard care plus BL therapy to see whether BL improves healing outcomes. Each participant will serve as their own comparison: two different DS areas on the same patient will receive the two different treatments.
Participants will:
After the DS have completely healed, participants will return for follow-up visits at 1 month and 3 months. During these visits, researchers will evaluate the quality of the scars and monitor for any late side effects.
Burn injuries frequently require surgical treatment with split-thickness skin grafting. This procedure involves harvesting skin from a healthy area of the body, commonly referred to as the donor site (DS). Although donor sites are considered superficial wounds, their healing process can be associated with clinically relevant complications, including delayed re-epithelialization, pain, inflammation, and risk of infection. These complications may prolong hospitalization, negatively affect patient comfort and quality of life, and influence the overall outcome of burn management. Therefore, strategies that may accelerate DS healing while maintaining safety and tolerability are of considerable clinical interest.
Photobiomodulation with blue light (BL) has emerged as a promising therapeutic approach in the management of several types of skin wounds. Experimental and clinical evidence suggests that BL may exert antimicrobial effects, modulate inflammatory processes, and stimulate tissue repair mechanisms involved in wound healing. These biological effects could potentially support faster re-epithelialization and improved wound bed conditions. However, clinical evidence specifically addressing the role of BL therapy in DS healing among burn patients remains limited.
This clinical investigation aims to evaluate the clinical effectiveness and safety of BL photobiomodulation when used in addition to the Standard of Care (SoC) for the treatment of DS wounds in patients undergoing skin grafting for burn injuries.
Study Design The study is designed as an interventional, controlled, prospective, single-center post-market clinical study. The intervention involves the use of a CE-marked medical device (EmoLED) that emits blue light and is already approved and routinely used in clinical practice in accordance with the manufacturer's indications and applicable regulatory standards.
The study will enroll 25 patients with intermediate or deep burn injuries who require surgical treatment with split-thickness skin grafting and who present at least two DS areas suitable for comparative evaluation.
To reduce inter-individual variability and improve the internal validity of the study, an intra-patient controlled design will be used. Each participant will serve as their own control. Two donor site areas will be assigned to different treatment modalities:
Study Procedures The day of the surgical intervention will be considered Day 0, during which the Case Report Form (CRF) will be prepared and baseline patient data will be collected. The DS areas will be measured and documented, including photographic documentation.
The experimental treatment with BL will begin at the first postoperative dressing change (Day 2) and will be repeated once per week for a total treatment duration of approximately 3-4 weeks, depending on the healing progression. BL will be applied to the entire donor site area for 60 seconds during each session using the study device.
DS assigned to the control arm will receive only the SoC, according to the wound care procedures routinely applied at the study center.
Clinical evaluation of both DS will be performed weekly during the treatment period, including completion of the CRF and collection of relevant clinical data. Each evaluation will include:
Data Sources and Data Collection
Data collected during the study will originate from source documents, including:
Data Quality Assurance
Several procedures will be implemented to ensure data validity, accuracy, and completeness, including:
Safety Monitoring Safety assessments will be conducted throughout the study in accordance with standard clinical practice and the study protocol.
The following safety parameters will be monitored:
Potential local adverse reactions to BL therapy may include:
All AE and SAE will be documented in the CRF, including:
Based on currently available evidence and the safety profile of the device, no specific risks related to study participation are anticipated beyond those associated with standard wound care procedures.
Protocol Deviations All protocol deviations will be identified, documented, and managed in compliance with Good Clinical Practice (GCP) and applicable regulatory requirements.
Potential deviations may include:
Statistical Analysis Plan Baseline demographic and clinical characteristics of enrolled patients will be summarized using descriptive statistics.
Because each patient contributes two DS, the statistical unit of analysis will be the individual wound, with paired observations within the same patient.
Comparisons between treatment modalities will be performed using paired statistical tests, selected according to the distribution and type of variables:
The time to complete wound healing will be analyzed using survival analysis techniques, including:
Handling of Missing Data Missing data may arise from incomplete assessments, missed follow-up visits, or documentation errors. When missing data occur, the circumstances will be documented in the CRF. Whenever possible, attempts will be made to retrieve missing information through review of medical records or contact with the patient.
Data that remain unavailable will be treated as missing values in the statistical analysis, and sensitivity analyses may be performed when appropriate to evaluate their potential impact on study results.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Standard treatment + Blue Light
Device: Photobiomodulation with blue light
Standard Treatment
The BL will be applied to the entire DS for 60 seconds, with one session per week, for a total of 3-4 weeks depending on the healing process.
Donor Site Healing Time
To compare the healing times of skin Donor Site treated with Standard of Care (SoC) in combination with Blue Light therapy compared to those treated with SoC.
Time frame: From enrollment to the end of treatment at 4-5 weeks
Wound Bed Score (WBS)
Compare skin Donor Site treated with SoC + Blue Light with those treated with SoC only, in relation to the characteristics of the wound bed, assessed using the Wound Bed Score (WBS) Modified scale. The scale ranges from 0 to 20, where higher scores indicate better wound bed conditions and improved healing potential.
Time frame: From enrollment to the end of treatment at 4-5 weeks
Numeric Pain Rating Scale (NRS)
Assess and compare the intensity of pain perceived by the patient during the healing period, using the Numeric Rating Scale (NRS), between areas treated with and without Blue Light therapy. The scale ranges from 0 to 10, where 0 indicates no pain and 10 indicates the worst pain imaginable; therefore, higher scores indicate worse pain.
Time frame: From enrollment to the end of treatment at 4-5 weeks
Signs of Infection
Assess the presence of signs of infection in the Donor Site by performing skin swabs on areas treated and not treated with Blue Light
Time frame: From enrollment to the end of treatment at 4-5 weeks
Local Adverse Reactions
Monitor the appearance of any local adverse reactions (e.g. redness, burning, heat sensation, skin irritation, itching) in Donor Site undergoing experimental treatment with Blue Light.
Time frame: From enrollment to the end of treatment at 4-5 weeks
Vancouver Scar Scale (VSS)
Compare the quality of scar outcomes at 1 and 3 months between the donor sites treated with SoC and those treated with SoC + Blue Light, using the Vancouver Scar Scale (VSS). The scale ranges from 0 to 13, where higher scores indicate more severe scar characteristics and worse scar quality.
Time frame: 1 and 3 months after healing
Plan to share: No
Started Sep 2025 (actual). Primary completion is estimated for Jul 2026, 10 months after the start.
Of 211 non-industry interventional studies with no phase under Burns, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 38. This study's planned 10 months is below that.
Counting every sponsor, half of 240 studies reached it within 15 months; a quarter within 6 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AUSL Romagna Rimini